CAR-T cells in the treatment of neurological autoimmune diseases

Practical Neurology 2026

View at publisher
Authors: Frederick William Vonberg, Benjamin E. Schroeder, Amy E. Edwards, Bo Sun, Ryan Yann Shern Keh, Mohammad Reza Ashraghi, Deanna Joe, Nikos Gorgoraptis, Jeremy H. Rees, N. Davies, Gerald T. Finnerty, Mark A. Willis
+5 more Maria Isabel Leite, R H Gold, Jeremias Motte, A. Carr, Stephen Keddie
DOI: 10.1136/pn-2025-004890
Cited by: 1
References: 110

Abstract

Chimeric antigen receptor T cells (CAR-T cells) have revolutionised cancer treatment by offering personalised therapy of unprecedented efficacy to patients with relapsed B-cell malignancies and myeloma. CAR-T cells are designed selectively to target CD19 or other B-cell antigens with high affinity, leading to a potent immune response and effective killing of malignant B cells. More recently, CAR-T treatment has been shown to be safe and effective in a very limited number of patients with severe, refractory autoimmune conditions such as systemic lupus erythematosus, systemic sclerosis and myositis. This paper describes the early use and feasibility of CAR-T therapies in the treatment of refractory autoimmune neurological diseases.

Fields of Study & Subjects

CAR-T cell therapy research Cutaneous lymphoproliferative disorders research Biotechnology and Related Fields

Publication details

Journal / source
Practical Neurology
Publisher
BMJ
Volume
26
Issue
5
Pages
pn–2025
Publication date
6 January 2026
Language
EN